Predicting response to anti-CD20 therapy in DLBCL patients
This invention provides methods, compositions, and kits relating to biomarkers whose expression levels are correlated with diffuse large B-cell lymphoma (DLCBL) patients' response to treatment with a CD20 antagonist, such as a CD20 antibody, exemplified by rituximab. The methods, compositions, and kits of the invention can be used to identify DLBCL patients who are likely or not likely, to respond to anti-CD20 treatments.
1. A method of assessing a patient with diffuse large B-cell lymphoma (DLBCL), comprising:
(a) obtaining a sample of the patient's tumor; and
(b) determining in the sample the level of expression of a gene combination consisting of U2AF1, RNF2, ZC3H7B, CCNI, PSMD11, ABLIM1, GYG2, CAMK2G, NF1, SEQ ID NO: 1, TRIM66, FBXO21, MKNK2, FYTTD1, GET4, CABLES2, FMNL3, C22orf27, TBCEL, ZNF707, SEQ ID NO: 2, CSTB, BAHCC1, LOC723809, NPIP, gene coding for cDNA FLJ40566 fis clone THYMU2004733, LOC730367, RXFP2, MGC24125, SEQ ID NO: 3, PTP4A1, OSBP, HNRNPD, AHCYL1, BMP2K, IDS, SERPINB9, CSRP2BP, CD58, HERC4, MAGOH, TMBIM4, SFRS12, FAS, ZNF333, SEQ ID NO: 4, USP6, CHD6, LOC653160, SEQ ID NO: 5, SRPR, MIR21, ARHGAP18, SEQ ID NO:6, CBFA2T2, TIMP3, CTBS, USP16, RASA1 and YJEFN3.
2. The method of claim 1 , wherein the patient is a candidate for anti-CD20 therapy.
3. The method of claim 2 , wherein the anti-CD20 therapy is rituximab.
4. The method of claim 1 , wherein the expression of the genes is measured by measuring the level of RNA transcribed from each gene.
5. The method of claim 1 , further comprising determining the level of expression of the genes listed in step (b) in a control set of samples comprising a representative number of patients that exhibit response to anti-CD20 therapy and a representative number of patients that exhibit no response or poor response to anti-CD20 therapy.
6. The method of claim 1 , wherein the level of expression is assessed using statistical methods.
7. A method of selecting a diffuse large B-cell lymphoma (DLBCL) patient for treatment with rituximab, comprising:
(a) obtaining a sample of the patient's tumor;
(b) detecting in the sample the expression of a gene combination consisting of U2AF1, RNF2, ZC3H7B, CCNI, PSMD11, ABLIM1, GYG2, CAMK2G, NF1, SEQ ID NO: 1, TRIM66, FBXO21, MKNK2, FYTTD1, GET4, CABLES2, FMNL3, C22orf27, TBCEL, ZNF707, SEQ ID NO: 2, CSTB, BAHCC1, LOC723809, NPIP, gene coding for cDNA FLJ40566 fis clone THYMU2004733, LOC730367, RXFP2, MGC24125, SEQ ID NO: 3, PTP4A1, OSBP, HNRNPD, AHCYL1, BMP2K, IDS, SERPINB9, CSRP2BP, CD58, HERC4, MAGOH, TMBIM4, SFRS12, FAS, ZNF333, SEQ ID NO: 4, USP6, CHD6, LOC653160, SEQ ID NO: 5, SRPR, MIR21, ARHGAP18, SEQ ID NO: 6, CBFA2T2, TIMP3, CTBS, USP16, RASA1 and YJEFN3;
(c) comparing the expression determined in step (b) to the expression of the same genes in a control set of samples comprising a representative number of patients that exhibit response to rituximab therapy and a representative number of patients that exhibit no response or poor response to rituximab therapy to determine if the patient is likely to respond to rituximab; and
(d) administering rituximab if the patient is determined likely to respond to rituximab.